Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Export

@article{citeulike:663631, abstract = {This article discusses platelet active drugs as part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. New data on antiplatelet agents include the following: (1) the role of aspirin in primary prevention has been the subject of recommendations based on the assessment of cardiovascular risk; (2) an increasing number of reports suggest a substantial interindividual variability in the response to antiplatelet agents, and various phenomena of "resistance" to the antiplatelet effects of aspirin and clopidogrel; (3) the benefit/risk profile of currently available glycoprotein IIb/IIIa antagonists is substantially uncertain for patients with acute coronary syndromes who are not routinely scheduled for early revascularization; (4) there is an expanding role for the combination of aspirin and clopidogrel in the long-term management of high-risk patients; and (5) the cardiovascular effects of selective and nonselective cyclooxygenase-2 inhibitors have been the subject of increasing attention.}, address = {University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy. cpatrono@unich.it}, author = {Patrono, C. and Coller, B. and FitzGerald, G. A. and Hirsh, J. and Roth, G.}, citeulike-article-id = {663631}, citeulike-linkout-0 = {http://dx.doi.org/10.1378/chest.126.3_suppl.234S}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15383474}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15383474}, doi = {10.1378/chest.126.3_suppl.234S}, issn = {0012-3692}, journal = {Chest}, keywords = {aas-cinetico}, month = {September}, number = {3 Suppl}, posted-at = {2006-05-21 18:18:15}, priority = {3}, title = {Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.}, url = {http://dx.doi.org/10.1378/chest.126.3_suppl.234S}, volume = {126}, year = {2004} }

TY - JOUR ID - citeulike:663631 L3 - citeulike-article-id:663631 N2 - This article discusses platelet active drugs as part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. New data on antiplatelet agents include the following: (1) the role of aspirin in primary prevention has been the subject of recommendations based on the assessment of cardiovascular risk; (2) an increasing number of reports suggest a substantial interindividual variability in the response to antiplatelet agents, and various phenomena of "resistance" to the antiplatelet effects of aspirin and clopidogrel; (3) the benefit/risk profile of currently available glycoprotein IIb/IIIa antagonists is substantially uncertain for patients with acute coronary syndromes who are not routinely scheduled for early revascularization; (4) there is an expanding role for the combination of aspirin and clopidogrel in the long-term management of high-risk patients; and (5) the cardiovascular effects of selective and nonselective cyclooxygenase-2 inhibitors have been the subject of increasing attention. IS - 3 Suppl JF - Chest SN - 0012-3692 AD - University of Rome La Sapienza, Via di Grottarossa 1035, 00189 Rome, Italy. cpatrono@unich.it TI - Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. VL - 126 KW - aas-cinetico AU - Patrono, C AU - Coller, B AU - FitzGerald, GA AU - Hirsh, J AU - Roth, G PY - 2004/09// UR - http://dx.doi.org/10.1378/chest.126.3_suppl.234S ER -